Drug intelligence / Profile preview

alpha 3 integrin shRNA

Development stage
Preclinical
Lead developer
AntiCancer
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

alpha 3 integrin shRNA is a short hairpin RNA-based research tool and potential therapeutic candidate designed to silence the expression of the alpha 3 integrin subunit (ITGA3). It functions through the RNA interference (RNAi) pathway, where the shRNA is processed into small interfering RNAs that guide the degradation of ITGA3 mRNA, thereby reducing the levels of the alpha 3 integrin protein. In preclinical research, specifically in orthotopic mouse models of pancreatic cancer, this shRNA has been delivered via lentiviral vectors to study the role of ITGA3 in tumor progression, cell adhesion, and metastasis. While it effectively achieves molecular knockdown, studies have indicated that silencing the alpha 3 subunit may not significantly inhibit tumor growth or metastasis in certain recalcitrant diseases like pancreatic cancer compared to other subunits such as beta 1 integrin.

Other names
ITGA3 shRNAITGA-3 shRNAITGA 3 shRNAintegrin alpha 3 shRNA
02

Targets

Integrin (Integrin family)

Beyond the preview

Go deeper on alpha 3 integrin shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha 3 integrin shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call